|
1.
|
Homburg R: Polycystic ovary syndrome. Clin
Obstet Gynaecol. 2:261–274. 2008.
|
|
2.
|
Lo JC, Feigenbaum SL, Yang J, Pressman AR,
Selby JV and Go AS: Epidemiology and adverse cardiovascular risk
profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol
Metab. 91:1357–1363. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Martin JF, Trowbridge EA, Salmon G and
Plumb J: The biological significance of platelet volume: its
relationship to bleeding time, platelet thromboxane B2 production
and megakaryocyte nuclear DNA concentration. Thrombosis Res.
1:443–460. 1983.PubMed/NCBI
|
|
4.
|
Senaran H, Ileri M, Altinbas A, Kosar A,
Yetkin E, Ozturk M, Karaaslan Y and Kirazli S: Thrombopoietin and
mean platelet volume in coronary artery disease. Clin Cardiol.
24:405–408. 2001.PubMed/NCBI
|
|
5.
|
Schneider DJ: Abnormalities of
coagulation, platelet function, and fibrinolysis associated with
syndromes of insulin resistance. Coron Artery Dis. 16:473–476.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Greisenegger S, Endler G, Hsieh K,
Tentschert S, Mannhalter C and Lalouschek W: Is elevated mean
platelet volume associated with a worse outcome in patients with
acute ischemic cerebrovascular events? Stroke. 35:1688–1691.
2004.PubMed/NCBI
|
|
7.
|
Endler G, Klimesch A, Sunder-Plassmann H,
et al: Mean platelet volume is an independent risk factor for
myocardial infarction but not for coronary artery disease. Br J
Haematol. 117:399–404. 2002.
|
|
8.
|
Gursoy A, Ertugrul DT, Pamuk B, et al:
Mean platelet volume in patients with polycystic ovary disease.
Platelets. 17:505–506. 2006.PubMed/NCBI
|
|
9.
|
Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group: Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary
syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
|
|
10.
|
Stein IF and Leventhal ML: Amenorrhoea
associated with bilateral polycystic ovaries. Am J Obst Gynecol.
29:181–191. 1935.
|
|
11.
|
Puzigaca Z, Prelevic GM, Stretenovic Z and
Balint-Peric L: Ovarian enlargement as a possible marker of
androgen activity in polycystic ovary syndrome. Gynecol Endocrinol.
5:167–174. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Watkin KL, Tulandi T, Mathur S and LeJeune
A: Three-dimensional visualisation of the polycystic ovary: effect
of ovarian drilling. Hum Reprod Update. 2(5): Item 18 (video),.
1996.
|
|
13.
|
Balen AH, Conway GS, Kaltsas G,
Techatraisak K, Manning P, West C and Jacobs HS: Polycystic ovary
syndrome: the spectrum of the disorder in 1741 patients. Hum
Reprod. 10:2107–2111. 1995.PubMed/NCBI
|
|
14.
|
Yildiz BO, Haznedaroglu IC, Kirazli S and
Bayraktar M: Global fibrinolytic capacity is decreased in
polycystic ovary syndrome, suggesting a prothrombotic state. J Clin
Endocrinol Metab. 87:3871–3875. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Talbott EO, Zborowski JV, Rager JR,
Boudreaux MY, Edmundowicz DA and Guzick DS: Evidence for an
association between metabolic cardiovascular syndrome and coronary
and aortic calcification among women with polycystic ovary
syndrome. J Clin Endocrinol Metab. 89:5454–5461. 2004. View Article : Google Scholar
|
|
16.
|
Kelly CJ, Speirs A, Gould GW, Petrie JR,
Lyall H and Connell JM: Altered vascular function in young women
with polycystic ovary syndrome. J Clin Endocrinol Metab.
87:742–746. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Palmert MR, Gordon CM, Kartashov AI, Legro
RS, Emans SJ and Dunaif A: Screening for abnormal glucose tolerance
in adolescents with polycystic ovary syndrome. J Clin Endocrinol
Metab. 87:1017–1023. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Apridonidze T, Essah PA, Iuorno MJ and
Nestler JE: Prevalence and characteristics of the metabolic
syndrome in women with polycystic ovary syndrome. J Clin Endocrinol
Metab. 90:1929–1935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Legro RS, Urbanek M, Kunselman AR, Leiby
BE and Dunaif A: Self-selected women with polycystic ovary syndrome
are reproductively and metabolically abnormal and undertreated.
Fertil Steril. 78:51–57. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kebapcilar L, Taner CE, Kebapcilar AG,
Alacacioglu A and Sari I: Comparison of four different treatment
regimens on coagulation parameters, hormonal and metabolic changes
in women with polycystic ovary syndrome. Arch Gynecol Obstet.
281:35–42. 2010. View Article : Google Scholar
|
|
21.
|
Thompson CB, Jakubowski JA, Quinn PG,
Deykin D and Valeri CR: Platelet size and age determine platelet
function independently. Blood. 63:1372–1375. 1984.PubMed/NCBI
|
|
22.
|
Rajendran S, Willoughby S, Chan W, et al:
Polycystic ovary syndrome is associated with severe platelet and
endothelial dysfunction in both obese and lean subjects.
Atherosclerosis. 204:509–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kebapcilar L, Taner CE, Kebapcilar AG and
Sari I: High mean platelet volume, low-grade systemic coagulation
and fibrinolytic activation are associated with androgen and
insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet.
280:187–193. 2009.PubMed/NCBI
|
